Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition.

Summary: Imagine inflammation as a fuel that helps cancer grow. Scientists have discovered a new "fire extinguisher" for this process: a class of molecules called furazanopyrazines. Instead of targeting just one part of the problem, these new compounds work by simultaneously blocking two different biological switches (enzymes called mPGES-1 and sEH). By flipping both switches off, these drugs disrupt the production of inflammatory chemicals, offering a promising two-pronged strategy to stop tumor growth and reduce inflammation.